Premium
Challenges in diagnosing hydroxychloroquine myopathy during the COVID ‐19 pandemic
Author(s) -
Pamphlett Roger,
Wang MinXia,
Chan Renee CF
Publication year - 2020
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.15092
Subject(s) - hydroxychloroquine , medicine , myopathy , weakness , covid-19 , pandemic , muscle weakness , intensive care medicine , pathology , surgery , disease , infectious disease (medical specialty)
Abstract Hydroxychloroquine is being used for COVID‐19 symptoms and in clinical trials, but can cause a toxic myopathy that leads to muscle weakness. A review of skeletal muscle biopsies from patients with hydroxychloroquine myopathy gives pointers of steps that can be taken to diagnose this toxic myopathy early and help differentiate it from COVID‐19‐related muscle weakness.